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Introduction. The aim of this study was to identify the antimalarials prescribed during the pregnancy and to document their
timing. Method. From June to September 2009, a survey was conducted on 565 women who gave birth in the Castors maternity
in Bangui. The antenatal clinics cards were checked in order to record the types of antimalarials prescribed during pregnancy
according to gestational age. Results. A proportion of 28.8% ANC cards contained at least one antimalarial prescription.
The commonest categories of antimalarials prescribed were: quinine (56.7%), artemisinin-based combinations (26.8%) and
artemisinin monotherapy (14.4%). Among the prescriptions that occurred in the ﬁrst trimester of pregnancy, artemisinin-based
combinations and artemisinin monotherapies represented the proportions of (10.9%) and (13.3%). respectively. Conclusion. This
study showed a relatively high rate (>80%) of the recommended antimalarials prescription regarding categories of indicated
antimalarials from national guidelines. But, there is a concern about the prescription of the artemisinin derivatives in the ﬁrst
trimester of pregnancy, and the prescription of artemisinin monotherapy. Thus, the reinforcement of awareness activities of health
care providers on the national malaria treatment during pregnancy is suggested.
1.Introduction
Malaria in pregnancy is a serious public health problem in
endemic regions. It is estimated that 85 millions pregnancies
occurred in Plasmodium falciparum malaria-endemic areas
[1].Thispathologyisamongthemaincausesofthelowbirth
weight (LBW) [2, 3], resulting from 3% to 8% neonatal and
infant deaths [3]. This led the World Health Organization
(WHO) to recommend a package of aﬀordable interventions
including the use of the insecticide-treated nets (ITNs), the
intermittent presumptive treatment (IPT) with sulfadoxine-
pyrimethamine (SP), and the eﬀective case management
of clinical malaria with recommended antimalarials. The
IPT with SP (IPT-SP) is given free of charge under direct
observedtherapy(DOT)duringtheantenatalclinics(ANCs)
at regular predeﬁned intervals of time [4], with the aim
to achieve the clearance of the existing Plasmodium falci-
parum asymptomatic infection (therapeutic eﬀect) and the
suppression of new maternal infections (prophylactic eﬀect)
over a period of time [5]. At least two doses of IPT-SP
are recommended during the second and third trimesters
of pregnancy [4]. The occurring of clinical malaria should
be treated with quinine or artemisinin-based combinations.
Quinine is considered to be a safe drug along all the period2 Malaria Research and Treatment
of the pregnancy, but safety data of artemisinin derivatives
during the ﬁrst trimester of pregnancy are limited [4], thus it
should not be prescribed in this period.
The integration approaches to these programmatic strat-
egies consist on the training and the supervision. Ongoing
assessments on the compliance of health care providers with
national policy on malaria treatment are needed. Actually,
no published data on prescribing practices in accordance to
these new strategies are available in Central African Republic
(CAR) and elsewhere.
Since 2006, the CAR malaria control programme is
implementing the WHO new guidelines on malaria man-
agement [4, 6]. The training seminars of the health care
providers (nurses, midwives and midwives assistants, med-
ical oﬃcers) from public and private health centers were
achieved. The supervision and the ﬁeld training visit are
scheduled each year at each health centre.
The aim of this study was to design a preliminary
assessment on the compliance of a trained staﬀ in the
malaria control new strategies at the main district maternity
in Bangui. Thus, we identiﬁed the antimalarials prescribed
for possible clinical malaria episodes during the pregnancy
and the timing proﬁle of those prescriptions according the
gestational age.
2. Methods
2.1. Study Design and Population. Our study was conducted
from June to September 2009 at one of the two main
maternities of Bangui city, the maternity of the Castors
government health centre. This health centre is located
in the most populated area of the city and is purposely
selected during this study as a representative pilot center
for the practice of the trained health care providers in
Bangui, regarding antimalarials prescription to pregnant
w o m e n .T h es t u d yi n v o l v e da l lw o m e nw h og a v eb i r t ha t
the Castors Health Centre maternity, and who have been
clinically followed up in the antenatal care services at this
same health centre. In April 2006, the ANC staﬀ (2 midwives
and 6 midwives assistants) has baseline training in the
malaria control new strategies and is regularly supervised
once per year accordingly. This was the key indication for
us to assess how the implementation of the new prescribing
recommendations is progressing. The average proportion of
pregnant women in Bangui who deliver in this maternity
each year is estimated at 35% (2500 deliveries) [7], and more
than95%ofthosewomenhavetheirANCvisitsinthishealth
centre (data checked from the centre registers).
Afterdelivery,allthewomenfromwhomwegotawritten
informed consent were immediately approached to record
the prescribed antimalarials from their antenatal clinics
(ANC) cards. Women who have not done all their ANC
visits at the Castors Health Centre were excluded from this
study. All the SP records were the IPT-SP, which is the only
antimalarial treatment given free of charge to the pregnant
women (direct observed therapy or DOT).
2.2. Ethical Approval. This study was undertaken during a
preliminary assessment of our project aiming at estimating
the burden of HIV infection on the malaria prevention
eﬀectiveness during pregnancy in CAR. This project was
reviewed and approved by the Scientiﬁc Committee Board
of The University of Bangui in charge of the validation of
scientiﬁc protocol studies in CAR. This study received the
agreement of the University of Marseille, France.
2.3. Data Analysis. Data were entered in EpiInfo software
version 3.5.1 (CDC, Atlanta, USA). An investigator checked
the EpiInfo data base and corrected errors identiﬁed after
referring to questionnaires. Data consistency was also ver-
iﬁed using Excel software (Microsoft Corporation), and
statistical analysis was achieved in Stata 8.0 (StataCorp
LP, USA). Findings are presented as frequencies and pro-
portions. Proportions were compared with the χ2-test (or
Fisher test), and a P v a l u ea tl e s st h a n0 . 0 5w a sc o n s i d e r e d
statistically signiﬁcant.
3. Results
A total of 565 women were enrolled for this study. Their
mean (±SD) age was 24.7 (±6.0) years (range: 15 to 45
years). A proportion of 21.8% (n = 123) has been given at
least one dose of IPT-SP. Only a proportion of 8.5% of them
was given more than one dose of IPT-SP, as is recommended
by the malaria control programme.
3.1. Prescribed Antimalarials. Overall, 163 pregnant women
(28.8%) were prescribed at least once an antimalarial for
a possible clinical malaria episode. The number of anti-
malarials prescription ranged from 1 to 3 times per ANC
cards. Eight ANC cards contained 3 prescriptions (4.9%),
and 29 ANC cards contained 2 prescriptions (17.8%). Over-
all, four diﬀerent groups of antimalarials were prescribed to
the 163 women during the pregnancy, and the total num-
ber of those prescriptions was 208 (the mean number of
antimalarials prescription per women was 1.28): quinine
(56.7%), artemisinin-based combinations (26.8%), arte-
misinin monotherapies (14.4%), and other antimalarials
monotherapies (chloroquine, halofantrine, and amodia-
quine). The malaria laboratory microscopy diagnosis was
available in the ANC cards for only 18.9% antimalarials
prescriptions (39/208). All those results were positive for
a Plasmodium falciparum, and the quinine was the only
antimalarial prescribed accordingly.
3.2.ProﬁleofAntimalarialsPrescribedaccordingtoGestational
Age. Antimalarials prescription began in the second month
of gestation, reaching a peak at the sixth month of gestation.
The global proportion of those prescriptions signiﬁcantly
increased from the ﬁrst trimester (16.8%) to the second
trimester (56.3%) (P value < 10−6). There were a total
of 85 artemisinin components prescriptions during the
current pregnancies (30 artemisinin monotherapies and 55
artemisinin-based combinations). Among those prescrip-
tions, four (13.3%) prescriptions of artemisinin monother-
apies and six (10.9%) artemisinin-based combinations pre-
scriptions occurred in the ﬁrst trimester of pregnancy. Oth-
erwise, we recorded a total number of 118 quinine prescrip-
tions.Malaria Research and Treatment 3
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Figure 1: Distribution of antimalarials prescribed during the
current pregnancy in the maternity of the Castors, Bangui, Central
African Republic: June to September 2009. Legend: CQ = Chloro-
quine, Hal = Halofantrine, and AQ = Amodiaquine.
The number of quinine prescription in the ﬁrst trimester
is24/35(68.6%)andinthesecondtrimester65/117(55.5%),
while artemisinin-based combinations are 6/35 (17.1%) for
the ﬁrst trimester and 40/117 for the second, and artemisinin
monotherapy is 4/35 (11.4%) for the ﬁrst trimester and
22/117 (18.8%) for the second.
Within each category of antimalarials, the distribution
trend increased from the ﬁrst trimester to the second
trimester: 24/118 (20.3%) to 65/118 (55.1%) for quinine,
6/55 (10.9%) to 30/55 (54.5%) for artemisinin-based combi-
nations, and 4/30 (13.3%) to 22/30 (73.3%) for artemisinin
monotherapies.
Details on the trend of those antimalarials prescription
according to pregnancy age are showed on Figure 1 (see
Supplementary Material available online at doi: 10.4061/
2011/414510).
4. Discussion
This study showed that nearly three years following the
change in national malaria control strategies during preg-
nancy, more than 80% of prescriptions represented the
recommended antimalarials (the quinine and artemisinin-
based combinations). The majority of pregnant women were
prescribed the quinine. The availability and aﬀordability of
thisantimalarialinthehealthcentrepharmacies(acurecosts
less than 2US$) could have motivated this preference. The
quinine is also preferred by the prescribers during malaria
management practices in Bangui, and the predominant
argument is the prompt evidence of its activity on malaria
symptoms [8].
Antenatal exposures to antimalarial drugs during the
pregnancy are a perpetual concern because there is limited
information on their safety. Indeed, pregnant women are
systematically excluded from clinical trials, hence the lack
of evidence bases on the toxicity of antimalarial drugs in
this population. Nevertheless, the obligation to treat (to
save lives) led to the use of antimalarials drugs during
pregnancy, as the experts agreed on the safety of the quinine
along all the period of the pregnancy and the artemisinin-
based combinations during the two last trimesters of the
pregnancy [6]. Thus, the prescription of the artemisinin
derivatives whichoccurredin theﬁrsttrimester ofpregnancy
is relevant because it is not advisable [4, 9]a n dm a yc a u s e
embryotoxicity [10] or enhance embryolethality risks [11].
This study showed also that health care providers pre-
scribed the artemisinin monotherapy. Thus, this regimen is
no longer recommended by WHO due to its short plasmatic
half-life, which could enhance the spreading of parasite
resistance and compromise the eﬃcacy of artemisinin-
based combinations [12]. It is also surprising that there
were 3 prescriptions of the chloroquine which has been
withdrawn from the CAR market because of its lack of
eﬃcacy on malaria [8]. This could be interpreted as a serious
prescription mistake.
This study has some limitations. The ﬁrst limitation was
the method used to record the prescriptions of antimalarial
drugs from solely ANC cards. Indeed, other antimalarials
taken by the women during their current pregnancies could
not have been reported in the ANC cards. However, record-
ing antimalarials use through interview could lead to error
because some pregnant women may not have accurately
recalled the name of the antimalarial prescribed and/or
taken, thus leading to biased ﬁndings on the health staﬀs
compliance with the national recommended guidelines.
The second limitation is that laboratory malaria analysis
results were poorly reported at the ANC visits cards. Thus,
we hypothesize that there has been a wide proportion of
presumptive treatment [13]. Indeed, the clinical symptoms
have not always the positive predictive value of malaria
[14, 15]. Another limitation is that the ﬁndings from this
study could be diﬀerent in other health maternities centres
due to changes of staﬀ (new health providers), or speciﬁcities
related to prescribing habits.
5. Conclusion
The ﬁndings of this study from a district maternity in Bangui
provide the indicator of the antimalarials groups prescribed
to pregnant women, during the period of the new malaria
treatment guidelines implementation in CAR. The observa-
tion from this study is that there is a satisfying adherence
by trained health care providers to the indicated categories
of antimalarials during pregnancy from the ANC staﬀ of
the Castors Health Center of Bangui. Nevertheless, there
are some errors of antimalarials prescription related to the
period of gestation and to not recommended antimalarials
prescriptions. The activities focusing on the supervision of
healthcareprovidersshouldbereinforcedtoassureadequate
malaria treatment during pregnancy according to national
guidelines. In particular, our ﬁndings helped the National
Malaria programme to enhance supervision activities to the4 Malaria Research and Treatment
staﬀ of Castors Maternity Centre in Bangui in order to lim-
ittheprescriptionerrorsinthefuture.Furtherstudiesassess-
ing the indicators of the national antimalarial policy imple-
mentation to the pregnant population are needed in other
areas of the country.
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